Crossmark

Temporal and spatial topography of cell proliferation in cancer

Crossref DOI link: https://doi.org/10.1038/s41556-022-00860-9

Published Online: 2022-03-15

Published Print: 2022-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gaglia, Giorgio https://orcid.org/0000-0002-5179-4256
Kabraji, Sheheryar https://orcid.org/0000-0002-5315-7103
Rammos, Danae

Dai, Yang

Verma, Ana https://orcid.org/0000-0001-9057-171X
Wang, Shu

Mills, Caitlin E.

Chung, Mirra

Bergholz, Johann S. https://orcid.org/0000-0003-4609-8448
Coy, Shannon

Lin, Jia-Ren https://orcid.org/0000-0003-4702-7705
Jeselsohn, Rinath

Metzger, Otto

Winer, Eric P.

Dillon, Deborah A.

Zhao, Jean J. https://orcid.org/0000-0002-4561-5688
Sorger, Peter K. https://orcid.org/0000-0002-3364-1838
Santagata, Sandro https://orcid.org/0000-0002-7528-9668
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (T32-HL007627)

American-Italian Cancer Foundation

Terri Brodeur Breast Cancer Foundation

Breast Cancer Research Foundation

U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32-GM007748)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA191058, P50-CA168504, P50-CA168504, P50-CA168504, R35-CA210057, R41-CA224503, U54-CA225088, U54-CA225088)

Dana-Farber/Harvard Cancer Center

U.S. Department of Defense (W81XWH-18-1-0491)

Ludwig Institute for Cancer Research

Brigham and Women’s Hospital President’s Scholar Award
License Information

Text and Data Mining valid from 2022-03-01

Version of Record valid from 2022-03-01
More Information

Article History

Received: 2 June 2021

Accepted: 31 January 2022

First Online: 15 March 2022

Competing interests

: P.K.S. is a member of the Scientific Advisory Board of RareCyte and NanoString Technologies, is on the Board of Directors of Applied Biomath and is a consultant to Merck and Montai Health. P.K.S. is co-founder of Glencoe Software, which contributes to and supports the open-source OME/OMERO image informatics software used in this paper. S.S. is a consultant for RareCyte, and J.J.Z. is a founder and board director of Crimson Biotech and Geode Therapeutics. J.S.B. is a scientific consultant and has stock options for Geode Therapeutics. D.A.D. is on the Advisory Board for Oncology Analytics and has consulted for Novartis. The other authors declare no competing interests.

Document is current

Any future updates will be listed below